ArticleJournal of lipid research2009
The role of oxidized phospholipids in atherosclerosis.
Article in Journal of lipid research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 400 citations in OpenAlex.
- Lipoprotein(a) lipidome and diet: responses to reducing saturated fat intake in African Americans in a randomized trial.Journal of lipid research · 2026Trial
- Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.Journal of lipid research · 2016Trial
- Seasonal variation in inflammatory biomarkers and blood pressure among patients with ischemic stroke: the influence of clinical confounding factors.BMC neurology · 2026Article
- Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update.Journal of clinical medicine · 2026Review
- Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target.Molecular biomedicine · 2026Review
- oxPAPC-Mediated lncRNA CYP1B1-AS1 From Dendritic Cells Accelerates Atherosclerosis.Journal of cellular and molecular medicine · 2026Article
- OxLDL-induced ferroptosis and pyroptosis in atherosclerosis: a mini review.Frontiers in immunology · 2026Review
- Lipoprotein(a) and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a).Atherosclerosis plus · 2025Article
- Evaluating Metabolic Signatures in the Serum of South Korean Patients with Humidifier Disinfectant-Associated Lung Injury Identified through Untargeted Metabolomics.Environmental health perspectives · 2025Article
- Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches.International journal of medical sciences · 2025Review
- Lipid Biochemistry and its Role in Human Diseases.Current medicinal chemistry · 2025Review
- The minimal membrane requirements for BAX-induced pore opening upon exposure to oxidative stress.Biophysical journal · 2024Article
- Lipoprotein(a) and cardiovascular disease.The Biochemical journal · 2024Review
- Selective regulation of macrophage lipid metabolism via nanomaterials' surface chemistry.Nature communications · 2024Article
- Understanding the Cardiovascular and Metabolic Health Effects of Air Pollution in the Context of Cumulative Exposomic Impacts.Circulation research · 2024Review
- Making Mountains out of Mole Hills: The Role of CD36 in Oxidized Phospholipid-driven Lung Injury.American journal of respiratory cell and molecular biology · 2024Article
- Single chain fragment variable, a new theranostic approach for cardiovascular diseases.Frontiers in immunology · 2024Review
- Targeting long non-coding RNA NUDT6 enhances smooth muscle cell survival and limits vascular disease progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Directly imaging emergence of phase separation in peroxidized lipid membranes.Communications chemistry · 2023Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
There is increasing evidence that oxidized phospholipids (OxPLs) play an important role in atherosclerosis. These phospholipids accumulate in human and mouse lesions. Specific OxPLs have been identified as major regulators of many cell types present in the vessel wall. In endothelial cells, >1,000 genes are regulated. Some of these genes are pro-atherogenic and others anti-atherogenic. The anti-atherogenic effects are likely important in slowing the atherogenic process. Several receptors and signaling pathways associated with OxPL action have been identified and shown to be upregulated in human lesions. A structural model of the mechanism by which specific OxPLs serve as CD36 ligands has been identified. Specific oxidized phospholipids are also present in plasma and associated with Lp(a) particles. In humans, OxPL/apolipoprotein B has been shown to be a prognostic indicator and a separate risk factor for coronary events. Levels of OxPL in plasma have been shown to be correlated with platelet activation. The results of these studies suggest an important role for OxPL in all stages of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.